author-photo

Lars Blumenstein

Novartis

37

Papers

347

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.

2021 Journal of Pharmaceutical Sciences
Show All
- Source
- Cite
- Save
Citations (0)
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

2019 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (107)
Alpelisib (BYL719) plus Fulvestrant in PIK3CA-altered and PIK3CA wild-type ER+ advanced breast cancer. An open-label, phase 1b dose-escalation and expansion study

2018
Show All
- Source
- Cite
- Save
Citations (0)
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (166)
Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
A phase Ib dose-finding study of alpelisib (ALP; BYL719) and paclitaxel (PTX) in advanced solid tumors (aST)

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Absorption, distribution, metabolism, and excretion of [ 14 C]BYL719 (alpelisib) in healthy male volunteers

2015 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (20)
Phase lb/ll study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (15)
Abstract 5476: LHRH receptor targeting as mechanism of anti-tumor activity for cytotoxic conjugates of Disorazol Z with the LHRH receptor agonistic peptide D-Lys6-LHRH.

2013 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)